| Amphetamine-type stimulants comprise of amphetamine, methamphetamine, MDMA (3,4-Methylenedioxymethamphetamine), as well as an increasing number of “designer” drugs. At SFGH, approximately 10% of samples that screen positive with the CEDIA amphetamine/Ecstasy immunoassay do not contain MDMA, MDA, amphetamine, or methamphetamine when subjected to LC-MS/MS for conformation. Goals: 1) Document the cross-reactivities of designer drugs to the CEDIA amphetamine/Ecstasy immunoassay. 2) Develop a LC-MS/TOF (time-of-flight) method that detects a comprehensive list of amphetamine-type stimulants. Over half of the designer drugs (12/23) tested exhibited significant cross-reactivity to the CEDIA immunoassay. LC parameters, LOD, and retention times were established for each of the designer drugs using Agilent 6230 LC-MS/TOF. |
|
